Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report). The associated price target remains the same with $6.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of Brainstorm Cell Therapeutics’ NurOwn cell therapy. The recent data from the Expanded Access Program (EAP) for amyotrophic lateral sclerosis (ALS) patients is particularly compelling, showing that 90% of the participants survived more than five years. This is a significant improvement over the typical ALS survival rate, where only about 10% of patients live beyond five years. Such results underscore the potential efficacy of NurOwn in extending survival for ALS patients.
Additionally, the alignment with the FDA on the Special Protocol Assessment (SPA) and chemistry, manufacturing, and controls (CMC) aspects for the upcoming P3b ENDURANCE trial further strengthens the company’s position. The promising survival data, coupled with regulatory progress, suggests that Brainstorm Cell Therapeutics is well-positioned to advance its therapeutic offerings. These factors collectively support McCarthy’s optimistic outlook and Buy rating for the company’s stock.
BCLI’s price has also changed moderately for the past six months – from $1.550 to $1.240, which is a -20.0% drop .